Magali Guffroy

AbbVie (United States) — United States

Medicine · Health Sciences

18h-index1.4kcitations123works3.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Monoclonal and Polyclonal Antibodies Research(46), HER2/EGFR in Cancer Research(33), CAR-T cell therapy research(32), Cell Adhesion Molecules Research(16), Cancer Research and Treatments(16)

Publications123 total

Investigation of bone toxicity in drug development: review of current and emerging technologies
Toxicological Sciences·2025· 3 cited
Toxicologic Pathology Forum*: Opinion on New Technologies and Trends Disrupting Drug Discovery and Development: How Can the Next Generation of Toxicologic Pathologists Be Prepared for Evolving Roles?
Toxicologic Pathology·2025· 1 cited
Scientific and Regulatory Policy Committee Points to Consider: Proposal and Recommendations to Reduce Euthanasia of Control Nonhuman Primates in Nonclinical Toxicity Studies
Toxicologic Pathology·2025
Immunohistochemistry-Free Enhanced Histopathology of the Rat Spleen Using Deep Learning
Toxicologic Pathology·2024
Points to consider regarding the use and implementation of virtual controls in nonclinical general toxicology studies
Regulatory Toxicology and Pharmacology·2024· 15 cited
Nonclinical Investigation of Cytokine Mitigation Strategies for T-cell–Engaging Bispecifics in the Cynomolgus Macaque
Journal of Immunotherapy·2024
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Nature·2023· 146 citedOpen Access
Toxicologic Pathology Forum Opinion Piece: Use of Virtual Control Groups in Nonclinical Toxicity Studies: The Anatomic Pathology Perspective
Toxicologic Pathology·2023· 7 cited
Figure S2 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Figure S1 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Data from Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
2023Open Access
Data from Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
2023Open Access
Table S3 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Supplementary Information from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Table S4 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Table S5 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Supplementary Information from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
Supplementary Data from Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
2023Open Access
Supplementary Data from Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
2023Open Access
Table S1 from PF-06804103, A Site-specific Anti-HER2 Antibody–Drug Conjugate for the Treatment of HER2-expressing Breast, Gastric, and Lung Cancers
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Edward Rosfjord(16), Puja Sapra(14), Hadi Falahatpisheh(13), Judy Lucas(12), Hans‐Peter Gerber(11), Lioudmila Tchistiakova(11), Justin Lucas(9), Christopher J. O’Donnell(9), Cynthia M. Rohde(9), Divya Mathur(8), Kerry Kelleher(8), Jonathon Golas(8), Andrea T. Hooper(7), Manoj B. Charati(7), Jonathan Golas(7), Kimberly Marquette(7), Frank Loganzo(7), Chad May(6), Frank Barletta(6), Bernard S. Buetow(6)